65 results about "Kras mutation" patented technology

The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and / or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein and / or a mutated KRAS gene or mutated KRAS protein in a tumor sample.

The invention discloses a kit, a primer, a probe and a detection agent for detecting tumor gene variation. The kit, the primer, the probe and the detection agent for detecting the tumor gene variationcan be used for detecting tumor driving gene EGFR mutation, KRAS mutation, BRAF mutation, HER2 mutation, MET mutation, EML4-ALK fusion and ROS1 fusion. The fluorescent probe for detecting tumor genevariation, disclosed by the invention, has the advantages that the fluorescent probe is specifically combined with a mutant type DNA template in the PCR process but not combined with a wild type DNA template, so that a mutant type amplification result generates a fluorescence signal, and a wild type amplification result does not generate the fluorescence signal; a final judging result is that themutant type amplification result has a Ct value and the wild type amplification result has no Ct value. The primer and the probe for detecting tumor gene variation, disclosed by the invention, have the advantages of high specificity, simple kit operation, high detection sensitivity and objective and accurate qualitation of tumor gene variation.

The invention discloses a cell autophagy inhibitor taking rubiaceae-type cyclopeptides as effective components. The cell autophagy inhibitor is particularly used for inhibiting KRAS mutation, particularly KRAS dependent tumor cell protective autophagy, and promoting tumor cell apoptosis. The inhibitor is preferably a nano-micelle injection and can be applied to preparation of medicines for treating and preventing KRAS related cancers such as colon cancers, rectal cancers, lung cancers and pancreatic cancers. The cell autophagy inhibitor can effectively inhibit tumor cell protective autophagy, the rubiaceae-type cyclopeptides serving as the effective components are wide in source, the extraction process is mature, dosage forms and pharmacy modes are diversified, and the inhibitor can be applied to treatment and prevention of the KRAS related cancers and has a wide clinical application prospect.

The present invention is based on a detection method of the 9 KRAS mutations Gly12Ser, Gly12Arg, Gly12Cys, Gly12Asp, Gly12Ala, Gly12Val, Gly13Asp, Gln61His and Gln61Leu, in a sample susceptible of containing one or more of such mutations, based on amplification of the sample with the primers of the present invention. Further, the present invention relates to (i) a kit which comprises, amongst its components, reagents for ARMS amplification including one or more of the primers of the present invention; (ii) the primers themselves; and (iii) use of the method, kit and primers of above, for the diagnosis / prognosis of a pathological condition in a patient, particularly, of cancer.

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.

Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.

The invention relates to methods of treating lung cancer using glutaminase inhibitors. In particular, results demonstrate that lung cancers characterized by an EGFR or KRAS mutation are treated by glutaminase inhibitors.

The invention provides a method for treating NSCLC, especially in cases of KRAS mutation, involving the administration of deforolimus.

The invention relates to the technical field of biology, in particular to application of KRAS (kirsten ratsarcoma viral oncogene) serving as a biomarker in pancreatic cancer and provides application of a substance for detecting G12V mutation in KRAS gene or active fragments thereof to preparation of a kit used for assessment of pancreatic cancer treatment effects and / or judgment of pancreatic cancer prognosis. According to discovery of remarkable correlation between KRAS mutation in pre-operation cfDNA and shortening of overall survival and progression-free survival, a prognosis value of KRAS cfDNA assessment is revealed, and a method of how to provide information for clinical treatment of patients suffering from the pancreatic cancer on the basis of cfDNA biomarker detection assistance is founded, and accordingly individual treatment of the pancreatic cancer can be promoted.

Methods are provided for the detection and treatment of cancers having a KRAS mutation, which KRAS mutation may drive tumorigenesis in the cancer. In some embodiments the KRAS+ cancer is a lung adenocarcinoma.